~~<i id='C2B50661EB'><strike id='C2B50661EB'><tt id='C2B50661EB'><pre id='C2B50661EB'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

explore

author：Wikipedia 2025-09-27 09:58:53 - browse：3

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： How to fix cancer clinical trials' diversity problem

hotspot

entertainment

hotspot

focus

1:14AseaturtleisseenatSeaTurtlesResearchRescueandRehabilitationCenterinMugla,TurkeyonAug.18,2021.Seb

WSS

Weighted lottery helped low

A public health expert passes on football's full body collisions for youths

Inside the rise of 'mukbang' eating videos

How to fix the rural physician shortage in the U.S.

A public health expert passes on football's full body collisions for youths

Biogen nominates mother of director’s child to replace him on board

focus

explore

hotspot

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

Apple is now the first public company to be valued at $3 trillion

Xenotransplantation trials will require adjusting expectations, experts say

As demand for Covid shots wanes, Moderna seeks its next success

Altering the blood type of lungs raises potential for universal organs for transplants

DIEP, the 'gold standard' of breast reconstruction, is under threat

House transparency, PBM reform bill gains bipartisan support

Hollywood unions extend contract negotiations for actors

Patients, doctors are clashing about side effects of hormonal birth control

entertainment

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Covid hospitalizations on the rise, Humana says

Biden administration plans revamp of organ transplant system

Living organ donors deserve priority status for transplants

Snackable artificial intelligence, expert AI, and the pharma industry

ALS advocates say criticism of new drugs misses bigger picture

entertainment

hotspot

focus

focus